Home | Founder | What's New | In The News | Consulting | |||||||
H1N1 Consulting Paradigm Shift Intervention Monitoring |
Audio:Nov17
Dec1
Dec13
Jan18
twitter
Commentary Published H5N1
One Change From Efficient Transmission The above comments from today’s Sciencexpress on “Restricted Data on H5N1 Influenza Transmission", highlights the folly of the attempts to censor the Science and Nature papers on the changes required for efficient transmission of H5N1 in a ferret model. The main points of the paper have been widely discussed. Only five changes in two genes produce efficient transmission without the loss of virulence after 10 passages in ferrets. Since the five changes were of known polymorphisms, and two labs had generated similar results, it was clear that the efficient transmission was straightforward and the current H5N1 in circulation posed a much greater risk than was widely appreciated. Recent cases in Shenzhen China or Bali Indonesia had a number of receptor binding domain changes, and earlies cases in Cambodia, Vietnam, China, Turkey, Azerbaijan, Iraq, and Egypt had PB2 E627K. The natural isolates used recombination to mix various receptor binding domain changes that had been published by the same labs in the Netherlands and United States that had achieved efficient transmission. Thus, the censoring of this data by Science and Nature is hazardous to the world’s health. Many lab isolates have not been published, and isolates may contain mixtures, so the “need to know” group extends well beyond those hwo have published sequences that are 1-3 changes from aerosloization. In addition to lab isolates, there is considerable diversity in H5N1 in poultry and human cases, and in some instances, such as Egypt, sequence data has been withheld for human cases identified after March, 2010. The limited number of additional changes required for transmission is minimal, and the required changes should be published immediately. Recombinomics
Presentations |
||||||||||
|
Webmaster:
webmaster@recombinomics.com
© 2012
Recombinomics. All
rights
reserved.